Follow the Swedish Orphan Biovitrum AB (publ) stock price and the full management transaction log of the company, a listed equity based in Finland. Shares are listed on FI FI, under the oversight of FIN-FSA. Operating in the Health Care sector, Swedish Orphan Biovitrum AB (publ) has published 8 public disclosures. Market capitalisation: €154.2bn. The latest transaction was filed on 25 March 2026 (Purchase). Among the most active insiders: Guido Oelkers. The full history is openly available.
8
Insider Decl.
0
Thresholds
€6m
7 ops.
Buy Volume
€446,604
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Swedish Orphan Biovitrum AB (publ) Buy (bullish), based on 12 analysts. Average price target: SEK 471.67.
36Σ signal
Buys €6m€446,604 Sells
Fundamental score
Ranked 14,619 of 25,921 companies
48.3
score / 100
Value
40
Quality
56
FCF yld3.3%
Earn yld0.3%
EV/EBITDA16.3x
ROE2.3%
Gross mgn78%
Net mgn1.7%
Debt/EBITDA1.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.